Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Leukemia & lymphoma·2025

Same author

Curative strategies for high-risk acute promyelocytic leukemia.

Current opinion in oncology·2025

Same author

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Cancer·2025

Same author

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.

Blood neoplasia·2025

Same author

Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant.

Blood advances·2025

Same author

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Blood advances·2025

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Growth factors in leukemia.

Olga Frankfurt¹, Martin S Tallman

¹Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA. o-frankfurt@northwestern.edu

Journal of the National Comprehensive Cancer Network : JNCCN

|March 6, 2007

Summary

Myeloid growth factors show modest benefits in reducing neutropenia duration for leukemia patients. However, they do not consistently improve survival or remission rates in most clinical trials.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Experiment Videos

Last Updated: Jul 16, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Myeloid growth factors like G-CSF and GM-CSF are used in leukemia treatment.
Their administration aims to mitigate chemotherapy side effects and enhance efficacy.

Purpose of the Study:

To evaluate the role of myeloid growth factors in managing acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
To assess their impact on neutropenia, infections, remission rates, and survival.

Main Methods:

Extensive review of multiple clinical trials involving growth factors in leukemia management.
Analysis of growth factors administered before, concurrently, or sequentially with chemotherapy.
Evaluation of growth factors as chemotherapy-sensitizing agents and as monotherapy.

Main Results:

Modest reduction in neutropenia duration observed, but without consistent correlation to infection severity or survival outcomes.
Attempts to enhance chemosensitivity and reduce drug resistance did not improve remission or survival rates.
Some recent reports indicate improved outcomes in younger AML patients with normal karyotype.

Conclusions:

Growth factors offer limited, inconsistent benefits in improving major clinical outcomes for most leukemia patients.
Evidence does not support concerns of growth factor-induced drug resistance, increased toxicity, or bone marrow failure.
Further research may clarify specific patient subgroups who could benefit from growth factor therapy.